Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4023009 | Journal Français d'Ophtalmologie | 2015 | 10 Pages |
Abstract
Our medium-term results suggest that combined subconjunctival injection of bevacizumab and photodynamic therapy with verteporfin might be used safely and effectively to reduce corneal neovascularization surface. This combined therapy may show a tendency toward greater efficacy than the individual monotherapies. Controlled prospective randomized multicentric trials with a larger sample size are necessary to assess long-term efficacy and to confirm these results.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
J. Hamdan, M. Boulze, A. Aziz, G. Alessi, L. Hoffart,